Alexandra L Quittner1, Anne E O'Donnell2, Matthias A Salathe3, Sandra A Lewis4, Xiaoming Li4, A Bruce Montgomery5, Thomas G O'Riordan4, Alan F Barker6. 1. Department of Psychology & Pediatrics, University of Miami, and Behavioral Health Sciences Research, Coral Gables, Florida, USA. 2. Division of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine, Georgetown University, Washington, District of Columbia, USA. 3. Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Miami, Miami, Florida, USA. 4. Gilead Sciences Inc., Seattle, Washington, USA. 5. Cardeas Pharma Corp., Seattle, Washington, USA. 6. Department of Medicine, Division of Pulmonary and Critical Care, Oregon Health & Science University, Portland, Oregon, USA.
Abstract
BACKGROUND: The Quality of Life-Bronchiectasis (QOL-B), a self-administered, patient-reported outcome measure assessing symptoms, functioning and health-related quality of life for patients with non-cystic fibrosis (CF) bronchiectasis, contains 37 items on 8scales (Respiratory Symptoms, Physical, Role, Emotional and Social Functioning, Vitality, Health Perceptions and Treatment Burden). METHODS: Psychometric analyses of QOL-B V.3.0 used data from two double-blind, multicentre, randomised, placebo-controlled, phase III trials of aztreonam for inhalation solution (AZLI) in 542 patients with non-CF bronchiectasis and Gram-negative endobronchial infection. RESULTS: Excellent internal consistency (Cronbach's α ≥0.70) and 2-week test-retest reliability (intraclass correlation coefficients ≥0.72) were demonstrated for each scale. Convergent validity with 6 min walk test was observed for Physical and Role Functioning scores. No floor or ceiling effects (baseline scores of 0 or 100) were found for the Respiratory Symptoms scale (primary endpoint of trials). Baseline Respiratory Symptoms scores discriminated between patients based on baseline FEV₁% predicted in only one trial. The minimal important difference score for the Respiratory Symptoms scale was 8.0 points. AZLI did not show efficacy in the two phase III trials. QOL-B responsivity to treatment was assessed by examining changes from baseline QOL-B scores at study visits at which protocol-defined pulmonary exacerbations were reported. Mean Respiratory Symptoms scores decreased 14.0 and 14.2 points from baseline for placebo-treated and AZLI-treated patients with exacerbations, indicating that worsening respiratory symptoms were reflected in clinically meaningful changes in QOL-B scores. CONCLUSIONS: Previously established content validity, reliability and responsivity of the QOL-B are confirmed by this final validation study. The QOL-B is available for use in clinical trials and routine clinical practice. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RCT Entities:
BACKGROUND: The Quality of Life-Bronchiectasis (QOL-B), a self-administered, patient-reported outcome measure assessing symptoms, functioning and health-related quality of life for patients with non-cystic fibrosis (CF) bronchiectasis, contains 37 items on 8 scales (Respiratory Symptoms, Physical, Role, Emotional and Social Functioning, Vitality, Health Perceptions and Treatment Burden). METHODS: Psychometric analyses of QOL-B V.3.0 used data from two double-blind, multicentre, randomised, placebo-controlled, phase III trials of aztreonam for inhalation solution (AZLI) in 542 patients with non-CF bronchiectasis and Gram-negative endobronchial infection. RESULTS: Excellent internal consistency (Cronbach's α ≥0.70) and 2-week test-retest reliability (intraclass correlation coefficients ≥0.72) were demonstrated for each scale. Convergent validity with 6 min walk test was observed for Physical and Role Functioning scores. No floor or ceiling effects (baseline scores of 0 or 100) were found for the Respiratory Symptoms scale (primary endpoint of trials). Baseline Respiratory Symptoms scores discriminated between patients based on baseline FEV₁% predicted in only one trial. The minimal important difference score for the Respiratory Symptoms scale was 8.0 points. AZLI did not show efficacy in the two phase III trials. QOL-B responsivity to treatment was assessed by examining changes from baseline QOL-B scores at study visits at which protocol-defined pulmonary exacerbations were reported. Mean Respiratory Symptoms scores decreased 14.0 and 14.2 points from baseline for placebo-treated and AZLI-treated patients with exacerbations, indicating that worsening respiratory symptoms were reflected in clinically meaningful changes in QOL-B scores. CONCLUSIONS: Previously established content validity, reliability and responsivity of the QOL-B are confirmed by this final validation study. The QOL-B is available for use in clinical trials and routine clinical practice. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Bronchiectasis; Perception of Asthma/Breathlessness; Respiratory Infection; Respiratory Measurement
Authors: Emily Henkle; Shannon A Novosad; Sean Shafer; Katrina Hedberg; Sarah A R Siegel; Jennifer Ku; Cara Varley; D Rebecca Prevots; Theodore K Marras; Kevin L Winthrop Journal: Ann Am Thorac Soc Date: 2017-07
Authors: Emily Henkle; Timothy Aksamit; Alan Barker; Charles L Daley; David Griffith; Philip Leitman; Amy Leitman; Elisha Malanga; Theodore K Marras; Kenneth N Olivier; D Rebecca Prevots; Delia Prieto; Alexandra L Quittner; William Skach; John W Walsh; Kevin L Winthrop Journal: Ann Am Thorac Soc Date: 2016-09
Authors: Sharon D Dell; Margaret W Leigh; Jane S Lucas; Thomas W Ferkol; Michael R Knowles; Adrianne Alpern; Laura Behan; Anjana M Morris; Claire Hogg; Audrey DunnGalvin; Alexandra L Quittner Journal: Ann Am Thorac Soc Date: 2016-10
Authors: Bumhee Yang; Hayoung Choi; Jun Hyeok Lim; Hye Yun Park; Danbee Kang; Juhee Cho; Jae Seung Lee; Sei Won Lee; Yeon-Mok Oh; Ji-Yong Moon; Sang-Heon Kim; Tae-Hyung Kim; Jang Won Sohn; Ho Joo Yoon; Hyun Lee Journal: Ann Transl Med Date: 2019-12
Authors: James D Chalmers; Kelly L Moffitt; Guillermo Suarez-Cuartin; Oriol Sibila; Simon Finch; Elizabeth Furrie; Alison Dicker; Karolina Wrobel; J Stuart Elborn; Brian Walker; S Lorraine Martin; Sara E Marshall; Jeffrey T-J Huang; Thomas C Fardon Journal: Am J Respir Crit Care Med Date: 2017-05-15 Impact factor: 21.405